Development and assessment of a novel spectrophotometric technique employing silver nitrate nanoparticles to identify pure and medicinal forms of Valsartan

Silver nanoparticles were attended by the interaction of silver nitrate (AgNO3) with the drug of valsartan (VAL) to create a Compound that produced the maximum absorption at a wavelength of 408 nm by selecting the optimal conditions for the interaction between the two compounds which were adopted in subsequent experiments. The study covers the development of a straightforward and precise spectrophotometry for the measurement of valsartan in pharmaceutical formulations and pure forms. The molar absorption rate was 3.3012×10−4 l.mol−1.cm−1, the correlation coefficient was 0.9988, the sandel sensitivity was 0.0131.µg.cm−2, and the Beer’s law limit was 5–40 µg.ml−1. When this technique was used to estimate the amount of Valsartan in pharmaceuticals, the composition of the resultant compound revealed that the detection limit (0.0478µg.ml−1), the quantitative limit (0.1451µg.ml−1), and the Rec value (95.0659 - 101.1697) were all within the range of 0.1534-0.2847. Additionally, the valsartan measurement approach has proven effectively. Characterizated silver nanoparticles by EDX and FE-SEM techniques, The EDX spectrum revealed the presence of silver atoms in the range of 3 keV, and the micrograph clearly shows that the particles are spherical in form and range in average size from 57.08 to 65.05 nm.